nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Ocular toxicity—Fluorouracil—head and neck cancer	0.0636	0.0636	CcSEcCtD
Tobramycin—Ototoxicity—Docetaxel—head and neck cancer	0.031	0.031	CcSEcCtD
Tobramycin—Platelet count decreased—Hydroxyurea—head and neck cancer	0.0201	0.0201	CcSEcCtD
Tobramycin—Application site pain—Fluorouracil—head and neck cancer	0.0196	0.0196	CcSEcCtD
Tobramycin—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.0188	0.0188	CcSEcCtD
Tobramycin—Lower respiratory tract infection—Docetaxel—head and neck cancer	0.0182	0.0182	CcSEcCtD
Tobramycin—Neurotoxicity—Docetaxel—head and neck cancer	0.016	0.016	CcSEcCtD
Tobramycin—Local reaction—Fluorouracil—head and neck cancer	0.0156	0.0156	CcSEcCtD
Tobramycin—Lacrimation—Fluorouracil—head and neck cancer	0.0146	0.0146	CcSEcCtD
Tobramycin—Creatinine increased—Hydroxyurea—head and neck cancer	0.0126	0.0126	CcSEcCtD
Tobramycin—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.0109	0.0109	CcSEcCtD
Tobramycin—Deafness—Vinblastine—head and neck cancer	0.0106	0.0106	CcSEcCtD
Tobramycin—Stinging—Fluorouracil—head and neck cancer	0.0106	0.0106	CcSEcCtD
Tobramycin—Lacrimation—Docetaxel—head and neck cancer	0.0106	0.0106	CcSEcCtD
Tobramycin—Eye irritation—Fluorouracil—head and neck cancer	0.0101	0.0101	CcSEcCtD
Tobramycin—Disorientation—Hydroxyurea—head and neck cancer	0.00971	0.00971	CcSEcCtD
Tobramycin—Renal failure acute—Hydroxyurea—head and neck cancer	0.0094	0.0094	CcSEcCtD
Tobramycin—Lacrimation increased—Fluorouracil—head and neck cancer	0.00934	0.00934	CcSEcCtD
Tobramycin—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00921	0.00921	CcSEcCtD
Tobramycin—Leukocytosis—Fluorouracil—head and neck cancer	0.00916	0.00916	CcSEcCtD
Tobramycin—Laryngeal pain—Docetaxel—head and neck cancer	0.00912	0.00912	CcSEcCtD
Tobramycin—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00813	0.00813	CcSEcCtD
Tobramycin—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00783	0.00783	CcSEcCtD
Tobramycin—Eye irritation—Docetaxel—head and neck cancer	0.00728	0.00728	CcSEcCtD
Tobramycin—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00722	0.00722	CcSEcCtD
Tobramycin—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00719	0.00719	CcSEcCtD
Tobramycin—Swelling—Fluorouracil—head and neck cancer	0.00708	0.00708	CcSEcCtD
Tobramycin—Chest discomfort—Docetaxel—head and neck cancer	0.00702	0.00702	CcSEcCtD
Tobramycin—Disorientation—Fluorouracil—head and neck cancer	0.00699	0.00699	CcSEcCtD
Tobramycin—Bone disorder—Docetaxel—head and neck cancer	0.00688	0.00688	CcSEcCtD
Tobramycin—Agranulocytosis—Vinblastine—head and neck cancer	0.00685	0.00685	CcSEcCtD
Tobramycin—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00683	0.00683	CcSEcCtD
Tobramycin—Lacrimation increased—Docetaxel—head and neck cancer	0.00674	0.00674	CcSEcCtD
Tobramycin—Oliguria—Docetaxel—head and neck cancer	0.00674	0.00674	CcSEcCtD
Tobramycin—Drug interaction—Docetaxel—head and neck cancer	0.0067	0.0067	CcSEcCtD
Tobramycin—Infestation—Hydroxyurea—head and neck cancer	0.00669	0.00669	CcSEcCtD
Tobramycin—Infestation NOS—Hydroxyurea—head and neck cancer	0.00669	0.00669	CcSEcCtD
Tobramycin—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00657	0.00657	CcSEcCtD
Tobramycin—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00656	0.00656	CcSEcCtD
Tobramycin—Pharyngitis—Vinblastine—head and neck cancer	0.00654	0.00654	CcSEcCtD
Tobramycin—Hearing impaired—Docetaxel—head and neck cancer	0.00653	0.00653	CcSEcCtD
Tobramycin—Stomatitis—Hydroxyurea—head and neck cancer	0.00652	0.00652	CcSEcCtD
Tobramycin—Lethargy—Fluorouracil—head and neck cancer	0.00638	0.00638	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00621	0.00621	CcSEcCtD
Tobramycin—Dry skin—Fluorouracil—head and neck cancer	0.00573	0.00573	CcSEcCtD
Tobramycin—Muscular weakness—Fluorouracil—head and neck cancer	0.00551	0.00551	CcSEcCtD
Tobramycin—Angiopathy—Hydroxyurea—head and neck cancer	0.00545	0.00545	CcSEcCtD
Tobramycin—Eosinophilia—Fluorouracil—head and neck cancer	0.00535	0.00535	CcSEcCtD
Tobramycin—Ill-defined disorder—Vinblastine—head and neck cancer	0.00532	0.00532	CcSEcCtD
Tobramycin—Anaemia—Vinblastine—head and neck cancer	0.0053	0.0053	CcSEcCtD
Tobramycin—Erythema—Hydroxyurea—head and neck cancer	0.00523	0.00523	CcSEcCtD
Tobramycin—Thrombophlebitis—Docetaxel—head and neck cancer	0.00521	0.00521	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00519	0.00519	CcSEcCtD
Tobramycin—Malaise—Vinblastine—head and neck cancer	0.00517	0.00517	CcSEcCtD
Tobramycin—Vertigo—Vinblastine—head and neck cancer	0.00515	0.00515	CcSEcCtD
Tobramycin—Leukopenia—Vinblastine—head and neck cancer	0.00513	0.00513	CcSEcCtD
Tobramycin—Swelling—Docetaxel—head and neck cancer	0.00511	0.00511	CcSEcCtD
Tobramycin—Deafness—Docetaxel—head and neck cancer	0.00504	0.00504	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00502	0.00502	CcSEcCtD
Tobramycin—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00485	0.00485	CcSEcCtD
Tobramycin—Anaemia—Hydroxyurea—head and neck cancer	0.00483	0.00483	CcSEcCtD
Tobramycin—Discomfort—Vinblastine—head and neck cancer	0.00482	0.00482	CcSEcCtD
Tobramycin—Infestation NOS—Fluorouracil—head and neck cancer	0.00482	0.00482	CcSEcCtD
Tobramycin—Infestation—Fluorouracil—head and neck cancer	0.00482	0.00482	CcSEcCtD
Tobramycin—Renal impairment—Docetaxel—head and neck cancer	0.00474	0.00474	CcSEcCtD
Tobramycin—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00472	0.00472	CcSEcCtD
Tobramycin—Malaise—Hydroxyurea—head and neck cancer	0.00472	0.00472	CcSEcCtD
Tobramycin—Stomatitis—Fluorouracil—head and neck cancer	0.00469	0.00469	CcSEcCtD
Tobramycin—Leukopenia—Hydroxyurea—head and neck cancer	0.00468	0.00468	CcSEcCtD
Tobramycin—Lethargy—Docetaxel—head and neck cancer	0.0046	0.0046	CcSEcCtD
Tobramycin—Thrombocytopenia—Vinblastine—head and neck cancer	0.00458	0.00458	CcSEcCtD
Tobramycin—Epistaxis—Fluorouracil—head and neck cancer	0.00454	0.00454	CcSEcCtD
Tobramycin—Sinusitis—Fluorouracil—head and neck cancer	0.00452	0.00452	CcSEcCtD
Tobramycin—Agranulocytosis—Fluorouracil—head and neck cancer	0.00449	0.00449	CcSEcCtD
Tobramycin—Anorexia—Vinblastine—head and neck cancer	0.00446	0.00446	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00442	0.00442	CcSEcCtD
Tobramycin—Discomfort—Hydroxyurea—head and neck cancer	0.0044	0.0044	CcSEcCtD
Tobramycin—Rhinitis—Fluorouracil—head and neck cancer	0.00433	0.00433	CcSEcCtD
Tobramycin—Pharyngitis—Fluorouracil—head and neck cancer	0.00429	0.00429	CcSEcCtD
Tobramycin—Paraesthesia—Vinblastine—head and neck cancer	0.0042	0.0042	CcSEcCtD
Tobramycin—Dehydration—Docetaxel—head and neck cancer	0.00419	0.00419	CcSEcCtD
Tobramycin—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00419	0.00419	CcSEcCtD
Tobramycin—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00418	0.00418	CcSEcCtD
Tobramycin—Skin disorder—Hydroxyurea—head and neck cancer	0.00415	0.00415	CcSEcCtD
Tobramycin—Dry skin—Docetaxel—head and neck cancer	0.00413	0.00413	CcSEcCtD
Tobramycin—Anorexia—Hydroxyurea—head and neck cancer	0.00407	0.00407	CcSEcCtD
Tobramycin—Decreased appetite—Vinblastine—head and neck cancer	0.00407	0.00407	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00406	0.00406	CcSEcCtD
Tobramycin—Pain—Vinblastine—head and neck cancer	0.004	0.004	CcSEcCtD
Tobramycin—Feeling abnormal—Vinblastine—head and neck cancer	0.00386	0.00386	CcSEcCtD
Tobramycin—Bronchospasm—Docetaxel—head and neck cancer	0.00383	0.00383	CcSEcCtD
Tobramycin—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00383	0.00383	CcSEcCtD
Tobramycin—Dyspnoea—Hydroxyurea—head and neck cancer	0.0038	0.0038	CcSEcCtD
Tobramycin—Erythema—Fluorouracil—head and neck cancer	0.00376	0.00376	CcSEcCtD
Tobramycin—Decreased appetite—Hydroxyurea—head and neck cancer	0.00371	0.00371	CcSEcCtD
Tobramycin—Abdominal pain—Vinblastine—head and neck cancer	0.0037	0.0037	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00368	0.00368	CcSEcCtD
Tobramycin—Pain—Hydroxyurea—head and neck cancer	0.00365	0.00365	CcSEcCtD
Tobramycin—Vision blurred—Fluorouracil—head and neck cancer	0.00355	0.00355	CcSEcCtD
Tobramycin—Weight decreased—Docetaxel—head and neck cancer	0.00353	0.00353	CcSEcCtD
Tobramycin—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00352	0.00352	CcSEcCtD
Tobramycin—Anaemia—Fluorouracil—head and neck cancer	0.00348	0.00348	CcSEcCtD
Tobramycin—Infestation NOS—Docetaxel—head and neck cancer	0.00348	0.00348	CcSEcCtD
Tobramycin—Infestation—Docetaxel—head and neck cancer	0.00348	0.00348	CcSEcCtD
Tobramycin—Hypersensitivity—Vinblastine—head and neck cancer	0.00345	0.00345	CcSEcCtD
Tobramycin—Renal failure—Docetaxel—head and neck cancer	0.00342	0.00342	CcSEcCtD
Tobramycin—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00341	0.00341	CcSEcCtD
Tobramycin—Stomatitis—Docetaxel—head and neck cancer	0.00339	0.00339	CcSEcCtD
Tobramycin—Body temperature increased—Hydroxyurea—head and neck cancer	0.00337	0.00337	CcSEcCtD
Tobramycin—Leukopenia—Fluorouracil—head and neck cancer	0.00337	0.00337	CcSEcCtD
Tobramycin—Asthenia—Vinblastine—head and neck cancer	0.00336	0.00336	CcSEcCtD
Tobramycin—Epistaxis—Docetaxel—head and neck cancer	0.00328	0.00328	CcSEcCtD
Tobramycin—Agranulocytosis—Docetaxel—head and neck cancer	0.00324	0.00324	CcSEcCtD
Tobramycin—Chest pain—Fluorouracil—head and neck cancer	0.0032	0.0032	CcSEcCtD
Tobramycin—Myalgia—Fluorouracil—head and neck cancer	0.0032	0.0032	CcSEcCtD
Tobramycin—Diarrhoea—Vinblastine—head and neck cancer	0.0032	0.0032	CcSEcCtD
Tobramycin—Discomfort—Fluorouracil—head and neck cancer	0.00317	0.00317	CcSEcCtD
Tobramycin—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00314	0.00314	CcSEcCtD
Tobramycin—Rhinitis—Docetaxel—head and neck cancer	0.00313	0.00313	CcSEcCtD
Tobramycin—Confusional state—Fluorouracil—head and neck cancer	0.0031	0.0031	CcSEcCtD
Tobramycin—Pharyngitis—Docetaxel—head and neck cancer	0.0031	0.0031	CcSEcCtD
Tobramycin—Dizziness—Vinblastine—head and neck cancer	0.00309	0.00309	CcSEcCtD
Tobramycin—Urinary tract disorder—Docetaxel—head and neck cancer	0.00308	0.00308	CcSEcCtD
Tobramycin—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00307	0.00307	CcSEcCtD
Tobramycin—Connective tissue disorder—Docetaxel—head and neck cancer	0.00307	0.00307	CcSEcCtD
Tobramycin—Asthenia—Hydroxyurea—head and neck cancer	0.00306	0.00306	CcSEcCtD
Tobramycin—Urethral disorder—Docetaxel—head and neck cancer	0.00306	0.00306	CcSEcCtD
Tobramycin—Nervous system disorder—Fluorouracil—head and neck cancer	0.00301	0.00301	CcSEcCtD
Tobramycin—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00301	0.00301	CcSEcCtD
Tobramycin—Visual impairment—Docetaxel—head and neck cancer	0.00301	0.00301	CcSEcCtD
Tobramycin—Vomiting—Vinblastine—head and neck cancer	0.00298	0.00298	CcSEcCtD
Tobramycin—Headache—Vinblastine—head and neck cancer	0.00293	0.00293	CcSEcCtD
Tobramycin—Anorexia—Fluorouracil—head and neck cancer	0.00293	0.00293	CcSEcCtD
Tobramycin—Diarrhoea—Hydroxyurea—head and neck cancer	0.00292	0.00292	CcSEcCtD
Tobramycin—Eye disorder—Docetaxel—head and neck cancer	0.00292	0.00292	CcSEcCtD
Tobramycin—Angiopathy—Docetaxel—head and neck cancer	0.00283	0.00283	CcSEcCtD
Tobramycin—Dizziness—Hydroxyurea—head and neck cancer	0.00282	0.00282	CcSEcCtD
Tobramycin—Immune system disorder—Docetaxel—head and neck cancer	0.00282	0.00282	CcSEcCtD
Tobramycin—Mediastinal disorder—Docetaxel—head and neck cancer	0.00281	0.00281	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.0028	0.0028	CcSEcCtD
Tobramycin—Nausea—Vinblastine—head and neck cancer	0.00278	0.00278	CcSEcCtD
Tobramycin—Paraesthesia—Fluorouracil—head and neck cancer	0.00276	0.00276	CcSEcCtD
Tobramycin—Dyspnoea—Fluorouracil—head and neck cancer	0.00274	0.00274	CcSEcCtD
Tobramycin—Erythema—Docetaxel—head and neck cancer	0.00272	0.00272	CcSEcCtD
Tobramycin—Vomiting—Hydroxyurea—head and neck cancer	0.00271	0.00271	CcSEcCtD
Tobramycin—Rash—Hydroxyurea—head and neck cancer	0.00269	0.00269	CcSEcCtD
Tobramycin—Dermatitis—Hydroxyurea—head and neck cancer	0.00269	0.00269	CcSEcCtD
Tobramycin—Headache—Hydroxyurea—head and neck cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Decreased appetite—Fluorouracil—head and neck cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Dysgeusia—Docetaxel—head and neck cancer	0.00266	0.00266	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00265	0.00265	CcSEcCtD
Tobramycin—Back pain—Docetaxel—head and neck cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Pain—Fluorouracil—head and neck cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Nausea—Hydroxyurea—head and neck cancer	0.00253	0.00253	CcSEcCtD
Tobramycin—Feeling abnormal—Fluorouracil—head and neck cancer	0.00253	0.00253	CcSEcCtD
Tobramycin—Anaemia—Docetaxel—head and neck cancer	0.00251	0.00251	CcSEcCtD
Tobramycin—Urticaria—Fluorouracil—head and neck cancer	0.00244	0.00244	CcSEcCtD
Tobramycin—Leukopenia—Docetaxel—head and neck cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Body temperature increased—Fluorouracil—head and neck cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Cough—Docetaxel—head and neck cancer	0.00237	0.00237	CcSEcCtD
Tobramycin—Chest pain—Docetaxel—head and neck cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Myalgia—Docetaxel—head and neck cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.0023	0.0023	CcSEcCtD
Tobramycin—Hypersensitivity—Fluorouracil—head and neck cancer	0.00226	0.00226	CcSEcCtD
Tobramycin—Confusional state—Docetaxel—head and neck cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Anaphylactic shock—Docetaxel—head and neck cancer	0.00222	0.00222	CcSEcCtD
Tobramycin—Nervous system disorder—Docetaxel—head and neck cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Pruritus—Fluorouracil—head and neck cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Thrombocytopenia—Docetaxel—head and neck cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Skin disorder—Docetaxel—head and neck cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Anorexia—Docetaxel—head and neck cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Diarrhoea—Fluorouracil—head and neck cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Dizziness—Fluorouracil—head and neck cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Paraesthesia—Docetaxel—head and neck cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Dyspnoea—Docetaxel—head and neck cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Vomiting—Fluorouracil—head and neck cancer	0.00195	0.00195	CcSEcCtD
Tobramycin—Rash—Fluorouracil—head and neck cancer	0.00194	0.00194	CcSEcCtD
Tobramycin—Dermatitis—Fluorouracil—head and neck cancer	0.00193	0.00193	CcSEcCtD
Tobramycin—Decreased appetite—Docetaxel—head and neck cancer	0.00193	0.00193	CcSEcCtD
Tobramycin—Headache—Fluorouracil—head and neck cancer	0.00192	0.00192	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Pain—Docetaxel—head and neck cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Feeling abnormal—Docetaxel—head and neck cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Nausea—Fluorouracil—head and neck cancer	0.00182	0.00182	CcSEcCtD
Tobramycin—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00181	0.00181	CcSEcCtD
Tobramycin—Abdominal pain—Docetaxel—head and neck cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Body temperature increased—Docetaxel—head and neck cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Hypersensitivity—Docetaxel—head and neck cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Asthenia—Docetaxel—head and neck cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Pruritus—Docetaxel—head and neck cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Diarrhoea—Docetaxel—head and neck cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Dizziness—Docetaxel—head and neck cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Vomiting—Docetaxel—head and neck cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Rash—Docetaxel—head and neck cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Dermatitis—Docetaxel—head and neck cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Headache—Docetaxel—head and neck cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Nausea—Docetaxel—head and neck cancer	0.00132	0.00132	CcSEcCtD
